Uttarakhand Ban: Patanjali Cries Conspiracy

New Delhi : Patanjali Ayurveda has claimed that rules prohibiting advertisements of certain drugs do not apply to ayurvedic medicines and the Uttarakhand regulatory authority’s order asking the company to stop production of five drugs is part of a “conspiracy” by “an anti-ayurveda drug mafia”.

The claims challenge the position of the Uttarakhand Ayurveda and Unani Services Licensing Authority in the BJP-ruled state that had in a November 9 letter directed the company to stop producing five drugs it promoted as treatment for blood pressure, diabetes, goitre, glaucoma and high cholesterol.

The authority, citing complaints by Kerala-based doctor K.V. Babu, had asked Divya Pharmacy, Patanjali’s manufacturing unit, to halt production of BPgrit, Eyegrit, Lipidom, Madhugrit and Thyrogrit, submit revised label claims and seek fresh approval for each.

Babu had complained that the advertisements violated the Drugs and Cosmetics Act, 1940, and the Magic Remedies Act, 1954.

The Acts prohibit advertisements that promote prevention, treatment, or cure of certain disorders, including blood pressure, glaucoma, goitre, diabetes, liver disorders and heart disease.

Divya Pharmacy, in a media release on Thursday, said it had received no such letter or information from the department “in any form”.

It also said the drug rules do not apply to ayurvedic medicines.

“We will not allow this conspiracy to succeed in any way. (The) Ayurveda and Unani Services (licensing authority) Uttarakhand involved in this conspiracy, bypassed the departmental responsibility by writing the… letter on 09.11.2022”, and releasing it for the media, Divya Pharmacy said.

Divya Pharmacy said the licensing authority should “rectify its mistake and take appropriate action against the person who is involved in the conspiracy or the Patanjali Institute will take legal action against the people responsible for this conspiracy”.

  • Related Posts

    Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

    The ministry of health and family welfare has declared the Pharmacy Council of India’s (PCI) recently notified regulation on the pharmacist recruitment, promotion and services as ultra vires and does…

    Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

    NAIROBI/GENEVA— In an alarming development that underscores the accelerating global crisis of antimicrobial resistance, researchers have confirmed the detection of a rare, pan-drug resistant strain of the high-priority fungal pathogen…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

    Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

    Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

    Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

    AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

    AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

    Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27

    Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27

    NDLEA Intercepts Massive ₦6.98 Billion Tramadol Shipment Imported from India at Lagos Port

    NDLEA Intercepts Massive ₦6.98 Billion Tramadol Shipment Imported from India at Lagos Port

    Two More Pregnant Women In Rajasthan’s Kota Die From Kidney Complications

    Two More Pregnant Women In Rajasthan’s Kota Die From Kidney Complications